This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant neoplasm of liver and intrahepatic bile ducts간 및 간내담관의 악성신생물 (간암)

📋 Contents and key points
A.Classification codes — C22 (Malignant neoplasm of liver and intrahepatic bile ducts)
B.Synonyms — Hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), hepatocellular cancer, primary liver cancer
C.Adult onset — Very high (mainly after the 40s; in Korea highest frequency in the 50s–60s)
1.History — Elucidation of the association of HBV and HCV with liver cancer; changes in liver cancer epidemiology in Korea; the IMbrave150 paradigm shift
2.Causes — Hepatitis B (HBV), hepatitis C (HCV), alcoholic cirrhosis, aflatoxin, NASH/MASLD
3.Genetics — TERT promoter (60%), TP53 (50%), CTNNB1 (40%), ARID1A (10–20%) mutations
4.Epidemiology — 6th in incidence and 3rd in mortality worldwide; about 15,000 cases per year in Korea; East Asia is a region of high HBV prevalence
5.Pathophysiology — HBV → chronic inflammation → cirrhosis → HCC; TP53 suppression by HBV X protein; aflatoxin G-T mutation
6.Symptoms — Right upper quadrant pain, jaundice, weight loss, ascites, fatigue, epigastric discomfort
7.Signs — Hepatomegaly, jaundice, ascites, spider angiomas, palmar erythema; elevated AFP, CA19-9, abnormal liver function tests
8.Screening — High-risk groups (cirrhosis, HBsAg-positive): abdominal ultrasound + AFP every 6 months; HBV vaccination
9.Diagnosis — Dynamic CT/MRI (arterial-phase enhancement + portal venous-phase washout); AFP; BCLC stage; Child-Pugh score
10.Treatment — Resection/RFA/TACE/SBRT/sorafenib/lenvatinib/atezolizumab + bevacizumab (IMbrave150)
11.Prognosis — BCLC 0–A 5-year survival 50–70%; BCLC C (advanced) median survival 19 months (atezo + bev)
12.Prevention — HBV vaccination, HCV direct-acting antiviral (DAA) treatment, abstinence from alcohol, avoidance of aflatoxin
13.References — Korean liver cancer practice guidelines, IMbrave150, REFLECT, SHARP, and others (10 in total)

Special Copayment Reduction (V193): 5% copayment applied for 5 years from the cancer patient registration date


A. Classification codes

CategoryDetails
ICD-10 codeC22 — Malignant neoplasm of liver and intrahepatic bile ducts
SubcodesC22.0 hepatocellular carcinoma (HCC), C22.1 intrahepatic cholangiocarcinoma (ICC), C22.2 hepatoblastoma, C22.3 angiosarcoma of liver, C22.4 other sarcomas, C22.7 other specified histologic types, C22.9 unspecified
Special Copayment Reduction codeV193
Main histological typesHCC (hepatocellular carcinoma) about 75–85%, ICC (intrahepatic cholangiocarcinoma) about 10–15%, mixed type about 2–5%

B. Synonyms

Liver cancer, hepatocellular carcinoma (HCC), intrahepatic cholangiocarcinoma (ICC), primary liver cancer, hepatocellular cancer (common term for liver cancer), hepatoblastoma (pediatric), angiosarcoma of liver. Clinically, 'liver cancer' often refers to HCC, but it covers all malignant tumors under code C22, including ICC. In English it is also called hepatocellular carcinoma, liver cell carcinoma, or hepatoma (an imprecise colloquial term).

C. Adult onset

Liver cancer is a disease with a very high frequency of adult onset. In Korea, the median age at HCC diagnosis is about 60 years, and it occurs most often in people in their 50s–70s. In East Asia, where chronic HBV infection is the main cause, it tends to occur at a somewhat younger age than in the West (mainly NASH-based). Hepatoblastoma is a separate clinical entity occurring mainly in children aged 5 or younger.


1. History

The history of liver cancer is so long that descriptions of jaundice and liver enlargement appear even in humanity's oldest writings. However, the concept of primary liver cancer in the modern sense was established in the late 19th century as pathologic classification became systematized. Hepatocellular carcinoma (HCC) was clearly recognized as an independent disease in the early 1900s, and its association with viral causes was elucidated only after the mid-20th century.

The association between hepatitis B virus (HBV) and liver cancer began when Baruch Blumberg discovered the Australia antigen (later named HBsAg) in 1965 and showed that it was a marker of HBV infection. Blumberg received the 1976 Nobel Prize in Physiology or Medicine for this work. Large epidemiologic studies in the 1980s–1990s then confirmed that the risk of HCC is increased more than 100-fold in people with chronic HBV infection. Hepatitis C virus (HCV) was identified in 1989 by Michael Houghton and colleagues (Nobel Prize 2020), and HCV was also shown to be a major cause of cirrhosis and HCC.

In Korea, liver cancer was one of the most common causes of cancer death until the introduction of the hepatitis B vaccine in 1983 and the establishment of national neonatal vaccination in 1995. After HBV vaccination, the HBsAg carrier rate fell from 7–8% in the early 1980s to less than 3% after the 2000s, and the incidence of liver cancer has accordingly been gradually declining, but Korea still ranks among the countries with the highest incidence in the world. The association between aflatoxin (aflatoxin B1) and liver cancer was first described in the UK in the 1960s and was identified as an important cause of HCC due to consumption of mold-contaminated food, especially in hot and humid regions of sub-Saharan Africa and Southeast Asia.

In the history of treatment, sorafenib was approved in 2008 after the SHARP trial as the first targeted agent for advanced HCC and held its place as first-line standard therapy for more than 10 years. In 2018, lenvatinib demonstrated noninferiority to sorafenib in the REFLECT trial and was added as a first-line option. In 2020, the IMbrave150 trial demonstrated that atezolizumab (PD-L1 inhibitor) + bevacizumab (anti-VEGF) was superior to sorafenib in both overall survival (OS) and progression-free survival (PFS), establishing it as first-line standard therapy for advanced HCC.

2. Causes

Viral causes

Hepatitis B virus (HBV) is the most important cause of HCC in East Asia including Korea, accounting for about 60–70% of all HCC. In people with chronic HBV infection, the annual incidence of HCC is 2–5% with cirrhosis and 0.1–0.4% even without cirrhosis. HBV carriers have a 5–100-fold increased relative risk of HCC compared with uninfected people. Hepatitis C virus (HCV) is the main cause of HCC in the West and Japan, with a high risk of progression from chronic HCV infection → cirrhosis → HCC. It has now been confirmed that eradicating HCV with direct-acting antivirals (DAA) before the cirrhotic stage can greatly lower HCC risk.

Nonviral causes

Alcoholic liver disease (cirrhosis) is the second major cause of HCC in the West, and the risk of progression from alcoholic cirrhosis → HCC increases markedly in chronic heavy drinkers. Nonalcoholic fatty liver disease (NAFLD/MASLD) and nonalcoholic steatohepatitis (NASH/MASH) have recently emerged in the West and Korea as causes of HCC even without cirrhosis. Aflatoxin B1 is a carcinogenic mycotoxin produced in corn, peanuts, and rice contaminated with Aspergillus flavus and A. parasiticus, and causes HCC by inducing a specific G→T mutation (hotspot mutation) at TP53 codon 249. In certain regions of Africa and Southeast Asia, the synergistic effect of HBV and aflatoxin raises HCC incidence extremely high.

Other causes

Chronic liver diseases such as primary biliary cirrhosis (PBC), autoimmune hepatitis, Wilson disease, alpha-1 antitrypsin deficiency, hemochromatosis, and cholestasis also raise HCC risk over the long term. Diabetes, obesity, and metabolic syndrome become risk factors for HCC through NAFLD.

3. Genetics

HCC is a cancer with complex genomic heterogeneity, and its mutation profile differs by cause. The most common somatic mutations, in order, are the TERT promoter (about 60%), TP53 (about 50%, especially HBV- and aflatoxin-related), CTNNB1 (β-catenin, about 40%, alcohol- and HCV-related), and ARID1A (about 10–20%).

Signaling pathway abnormalities: the Wnt-β-catenin pathway (CTNNB1, AXIN1), cell-cycle regulation (RB1, CDKN2A, CCND1), the PI3K-AKT-mTOR pathway, and the RTK/RAS/MAPK pathway are the main drivers. TP53 variants are more common in HBV-related HCC, and CTNNB1, ARID1A, and ARID2 variants are more frequent in alcohol-related HCC. The TP53 codon 249 Arg→Ser hotspot variant is characteristic of aflatoxin-exposed HCC.

Molecular subtypes: broadly divided into a proliferative subtype (TP53 variants/low WNT activation, poor prognosis) and a non-proliferative subtype (CTNNB1 activation, relatively favorable prognosis). TERT promoter mutations evade replicative senescence through telomere maintenance, enabling unlimited proliferation of tumor cells. ICC is characterized by IDH1/2 (about 15–20%), FGFR2 fusions (about 10–15%), and BAP1 and PBRM1 variants. Hereditary liver cancer is rare, but increased liver cancer risk has been reported in BRCA1/2 variant carriers.

4. General epidemiology

Liver cancer (primary liver cancer) is a major malignancy worldwide, 6th in incidence and 3rd in cancer mortality. Annual new cases worldwide are estimated at about 900,000 and deaths at about 830,000 (GLOBOCAN 2020). Incidence varies markedly by region, with East Asia (China, Korea, Japan, Vietnam) and sub-Saharan Africa accounting for more than about 70% of cases worldwide.

In Korea, about 15,000 new cases of liver cancer occur per year as of 2022, about 3–4 times more in men than in women. Korea ranks among the top countries in the world for liver cancer incidence, with chronic HBV infection and a heavy drinking culture as the main background. After introduction of national HBV vaccination (1983), new HBV infections fell markedly, and the HBsAg carrier rate dropped from 7–8% in the 1980s to below about 3% in 2022 (0.2% or less in children). Nevertheless, liver cancer continues to occur among existing people with chronic HBV infection (estimated at about 1.0–1.3 million).

Recently in Korea, the proportion of HCC related to alcoholic liver disease and NAFLD has been increasing, while the proportion of HBV- and HCV-related HCC is relatively decreasing. Looking at changes in treatment patterns from 2008 to 2022, the proportions of surgical resection and systemic therapy increased, while the proportion of transarterial chemoembolization (TACE) decreased.

5. Pathophysiology

The pathogenesis of HCC is understood as a multistep carcinogenic process of chronic liver injury → inflammation → fibrosis → cirrhosis → HCC. HBV integrates viral DNA into hepatocytes (viral integration), causing genomic instability, and the HBx protein has direct carcinogenic effects through transcriptional repression of TP53, activation of Wnt signaling, and mitochondrial dysfunction. HCV raises HCC risk without hepatocyte integration by causing oxidative stress and steatosis through chronic inflammation.

Cirrhosis itself is also a strong risk factor for HCC. In fibrotic liver tissue, multistep progression occurs from regenerative nodule → dysplastic nodule → early HCC → advanced HCC. After activation in the body, aflatoxin B1 causes a G→T transversion at TP53 codon 249, abolishing the tumor-suppressive function of p53. TERT promoter mutations restore telomerase activity, enabling unlimited division of tumor cells. CTNNB1 variants cause nuclear accumulation of β-catenin and overexpression of Wnt target genes (cyclin D1, c-Myc, etc.), promoting cell proliferation. Loss of ARID1A function damages the SWI/SNF chromatin remodeling complex, impairing transcription of other tumor suppressor genes.

6. Symptoms

Early symptoms

Most early HCC is asymptomatic and is often found by regular screening. By the time symptoms appear, the disease is often considerably advanced. Right upper quadrant pain or discomfort is the most common symptom, caused by stretching of the liver capsule or tumor hemorrhage. Weight loss, general fatigue, and loss of appetite are also common nonspecific symptoms.

Advanced symptoms

Jaundice occurs when the tumor compresses the bile ducts, or due to reduced liver function or hilar lymph node metastasis. Ascites results from worsening portal hypertension, hypoalbuminemia, or peritoneal dissemination of the tumor; when accompanied by acute abdominal pain and signs of peritoneal irritation, spontaneous tumor rupture should be suspected. Edema, splenomegaly, and variceal bleeding may also accompany as complications of cirrhosis.

7. Signs

On physical examination, hepatomegaly (sometimes with a nodular surface or palpable epigastric mass), jaundice, ascites, spider angiomas, palmar erythema, gynecomastia in men, and splenomegaly (with cirrhosis) are observed. In hepatic encephalopathy, asterixis (flapping tremor) may appear.

Murphy's sign is specific to cholecystitis, but right upper quadrant tenderness is also common in HCC. Serum AFP (alpha-fetoprotein) is the most important serum tumor marker for HCC; values above normal (10 ng/mL or less) strongly suggest liver cancer, and 400 ng/mL or higher is highly significant diagnostically. However, AFP has a sensitivity of about 60% and specificity of about 80%, so a normal value cannot exclude HCC. DCP (PIVKA-II) is another tumor marker used complementarily with AFP. Abnormal liver function (elevated ALT, AST, ALP, GGT, bilirubin), hypoalbuminemia, and prolonged prothrombin time reflect reduced liver function.

8. Screening

The Korean National Cancer Screening Program provides free abdominal ultrasound and AFP testing every 6 months to groups at high risk of liver cancer (people aged 40 or older with cirrhosis or positive for hepatitis B antigen, positive for HCV antibody, or with a history of liver cancer). This program has been reported to raise the rate of early HCC detection and contribute to improved survival. The Korean Liver Cancer Association practice guidelines also recommend the same principles for screening high-risk groups.

HBV vaccination is the most effective means of primary prevention of HCC. In Korea it was introduced in 1983 under the national immunization program, with vaccination of newborns and infants, and as a result the HBsAg carrier rate in children fell from 8% in the 1980s to less than 0.2% after the 2000s. In people with chronic HBV infection, antiviral treatment with entecavir or tenofovir significantly reduces the risk of HCC. In people with HCV infection, viral eradication with DAA (direct-acting antivirals) also lowers HCC risk.

9. Diagnosis

Imaging diagnosis

Dynamic CT (triple-phase CT) or liver MRI is central to the noninvasive diagnosis of HCC. Owing to its dependence on hepatic arterial blood flow, HCC characteristically shows enhancement in the arterial phase followed by washout in the portal venous phase, and this typical pattern alone allows a diagnosis of HCC in lesions ≥1 cm on a background of chronic liver disease. The LI-RADS classification system systematically categorizes the likelihood of HCC for liver lesions. Liver MRI uses gadolinium contrast, with higher sensitivity especially when a hepatocyte-specific contrast agent (Primovist, gadoxetate disodium) is used.

AFP and other markers

AFP of 400 ng/mL or higher is highly significant diagnostically, but HCC can be present even with a normal AFP. DCP (PIVKA-II) and the AFP-L3 fraction are also used as adjuncts.

Biopsy and staging

When imaging cannot confirm the diagnosis, percutaneous biopsy under ultrasound or CT guidance is performed. The BCLC (Barcelona Clinic Liver Cancer) staging system is the most widely used internationally, integrating tumor factors (size, number, vascular invasion), liver function (Child-Pugh score), and the patient's general condition (ECOG PS). BCLC 0–A (early): indication for resection, RFA, or transplantation; BCLC B (intermediate): TACE; BCLC C (advanced): systemic therapy; BCLC D (terminal): palliative care. AJCC TNM 8th edition is also used in parallel.

10. Treatment

Curative treatment

Hepatic resection is first-line treatment for single or few lesions at BCLC stage 0–A with sufficient remnant liver function. Liver transplantation is a curative treatment that also treats the cirrhosis for HCC within the Milan criteria (single ≤5 cm, or up to 3 lesions each ≤3 cm), with a low recurrence rate. Radiofrequency ablation (RFA) provides local cure rates similar to resection for lesions of 3 cm or less, or when resection is not possible. Microwave ablation (MWA) is also used.

Topical treatment

Transarterial chemoembolization (TACE) is the standard local treatment for BCLC B (intermediate) stage HCC, embolizing the tumor by intra-arterial infusion of doxorubicin- or epirubicin-based drugs with Lipiodol/Gelfoam. Drug-eluting beads (DEB-TACE) show efficacy similar to conventional cTACE. SBRT (stereotactic body radiotherapy) is used when there is vascular invasion or refractoriness to TACE, or for lesion control while awaiting transplantation.

Systemic therapy

First-line standard systemic therapy for advanced HCC is atezolizumab + bevacizumab (IMbrave150), with median OS of 19.2 months (superior to 13.4 months with sorafenib). Sorafenib (SHARP trial) and lenvatinib (REFLECT trial, noninferior to sorafenib) are also first-line options. As second-line treatment, regorafenib (progression after sorafenib), cabozantinib, ramucirumab (AFP ≥400 ng/mL), nivolumab, and pembrolizumab are used. The Korean liver cancer practice guidelines (2022 edition) systematize these in line with domestic circumstances.

11. Prognosis

The prognosis of HCC differs greatly by stage, liver function (Child-Pugh score), and tumor characteristics. For BCLC 0 (very early, very small single lesion), 5-year survival after resection is about 70–90%. BCLC A: 5-year survival after resection about 50–70%. BCLC B: median survival after TACE about 26–40 months. BCLC C (advanced, vascular invasion/distant metastasis): median OS 19.2 months with atezolizumab + bevacizumab (IMbrave150). BCLC D (terminal, Child-Pugh C): median survival of only 3–4 months.

The most important prognostic factors are stage at diagnosis and remnant liver function. Patients with Child-Pugh A (good liver function) have broader treatment options and higher survival than those with C. Accompanying portal vein tumor thrombosis (PVTT) predicts a poor prognosis. The ALBI (albumin-bilirubin) score is also used for prognostic assessment of liver function.

12. Prevention

HBV vaccination: the most effective means of primary prevention of liver cancer. Included in Korea's National Immunization Program (NIP), given in 3 doses starting right after birth. Newborns of HBsAg-positive mothers receive HBIG + vaccine simultaneously immediately after birth. In people with HBV infection, viral suppression with antiviral treatment (entecavir, tenofovir) significantly lowers the risk of HCC.

HCV treatment: complete HCV eradication (SVR) with pangenotypic DAA (sofosbuvir/velpatasvir, glecaprevir/pibrentasvir, etc.) lowers the risk of cirrhosis and HCC. Moderation of or abstinence from alcohol: to prevent alcoholic cirrhosis, limit drinking to within WHO recommended amounts; patients with cirrhosis should abstain completely. Avoiding aflatoxin: improve food storage in hot and humid regions and refrain from eating mold-contaminated food. Managing obesity and diabetes: reduce HCC risk by preventing NAFLD/NASH through weight control and diabetes treatment.


13. References

  1. Korean Liver Cancer Association, National Cancer Center. Practice Guidelines for Liver Cancer 2022. Seoul: Korean Liver Cancer Association; 2022.
  2. Finn RS, Qin S, Ikeda M, et al. Atezolizumab plus bevacizumab in unresectable hepatocellular carcinoma (IMbrave150). N Engl J Med. 2020;382(20):1894-1905.
  3. Kudo M, Finn RS, Qin S, et al. Lenvatinib versus sorafenib in first-line treatment of patients with unresectable hepatocellular carcinoma: a randomised phase 3 non-inferiority trial (REFLECT). Lancet. 2018;391(10126):1163-1173.
  4. Llovet JM, Ricci S, Mazzaferro V, et al. Sorafenib in advanced hepatocellular carcinoma (SHARP). N Engl J Med. 2008;359(4):378-390.
  5. Park JW, Chen M, Colombo M, et al. Global patterns of hepatocellular carcinoma management from diagnosis to death: the BRIDGE Study. Liver Int. 2015;35(9):2155-2166.
  6. Korean Liver Cancer Association; National Cancer Center. 2022 KLCA-NCC Korea Practice Guidelines for the Management of Hepatocellular Carcinoma. Korean J Radiol. 2022;23(12):1126-1240.
  7. Sung H, Ferlay J, Siegel RL, et al. Global cancer statistics 2020: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries. CA Cancer J Clin. 2021;71(3):209-249.
  8. Schulze K, Imbeaud S, Letouze E, et al. Exome sequencing of hepatocellular carcinomas identifies new mutational signatures and potential therapeutic targets. Nat Genet. 2015;47(5):505-511.
  9. National Comprehensive Cancer Network. NCCN Clinical Practice Guidelines in Oncology: Hepatobiliary Cancers. Version 2.2025. Fort Washington, PA: NCCN; 2025.
  10. Kim BK, Kim SU, Park JY, et al. Evolving trends in epidemiology, etiology, and treatment patterns for hepatocellular carcinoma in South Korea. J Liver Cancer. 2024. doi:10.17998/jlc.2024.12.04.